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Abstract
Background: Autism is a neurodevelopmental disorder that clinically presented as cognitive deficits, social impairments
and sensory dysfunction. An increasing body of evidence has shown that oxidative stress and inflammation are involved
in the pathophysiology of autism. Recording biomarkers as measure of the severity of autistic features might help in
understanding the pathophysiology of autism.
Methods: This study investigates the plasma levels of 8-isoprostane and Cysteinyl leukotrienes (CysLTs) in 44 autistic
children and 40 healthy controls. The recruited autistic patients were assessed for behavior, cognitive and sensory
deficits by using different autism severity rating scales, including the Childhood Autism Rating Scales (CARS), Social
responsiveness scale (SRS) and Short Sensory Profile (SSP). Receiver Operating Characteristics analysis (ROC) of the
obtained data was performed to measure the predictive value of 8-isoprostane and Cysteinyl leukotrienes (CysLTs)
as oxidative stress- related parameters. Pearson’s correlations between the measured parameters was also performed.
Results: The concentrations of 8-isoprostane and CysLTs in autistic patients were significantly higher than those in
controls. While cognitive and social impairments did not show any significant differences, the SSP results were strongly
correlated with the levels of both of the biomarkers assessed. However, autistic children showed improvements in
oxidative stress status (as determined by 8-isoprostane levels) at increasing ages.
Conclusion: This study indicates that 8-isoprostane and CysLTs can be used as markers for the early recognition of
autistic patients through sensory deficits phenotypes which might help early intervention.
Keywords: Autism, Oxidative stress, Neuro-inflammation, 8-isoprostane, Cysteinyl leukotriene, Childhood autism rating
scale, Social responsiveness scale, Short sensory profile
Background
Autism is a neurodevelopmental disorder that is character-
ized by social interaction impairment, repetitive behavior,
cognition difficulties, and sensory dysfunction [1–3]. Ap-
proximately 1 out of 50 children are currently affected with
autism in the US [4]. As multifactorial disorder, autism is
considered a highly heterogeneous disorder with many
causes and associated factors resulting in variable ranges of
clinical presentations and severity. Genetics, environmental
interaction, impaired detoxification, immune dysregulation,
inflammation and oxidative stress are the main factors
contributed in autism pathogenesis; a clear cause for autism
has not been identified to date [5, 6].
Neuro-inflammation, which is described as specific and
chronic glial reactions that occur in the CNS, has been im-
plicated in autism [7, 8]. It can cause brain damage through
increased proinflammatory cytokine release and abnormal
neuronal growth [8–10]. Oxidative stress is usually thought
to be the major contributor and the primary cause of brain
damage and inflammation [11, 12].
In the early developmental stages of childhood, the
vulnerability of the brain to oxidative stress, measured
as abundance of reactive oxygen species (ROS), low
antioxidant capacity, and high levels of lipid content
is identified as a major factor that might increase
oxidative stress in autism [13]. Many studies have
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reported that lipid peroxidation products are much
higher in autistic patients compared to healthy con-
trols [14–16]. In addition, decreased levels of antioxi-
dants and detoxifying agents in samples from autistic
children has been reported [17–20]. A strong correl-
ation has been observed between low levels of the an-
tioxidants and impairments in language skills [14].
Polyunsaturated fatty acid residues in membrane
phospholipids are very sensitive to oxidative stress;
ROS may induce the breakdown of lipids, which can
disrupt the composition of membrane phospholipids
and alter neuronal function. Proinflammatory cytokines
that are released from glial cells can up regulate the
transcription of arachidonic acid (AA) metabolism-
related genes, among which are cytosolic phospholipase
A2 (cPLA2), secretory PLA2 (sPLA2), and cyclooxygenase-
2 (COX-2) [21–23].
The released AA can be converted through the action
of COX and lipoxygenase (LOX), into the proinflamma-
tory lipid mediators, prostaglandins (PG) and leukotri-
enes, respectively or through non-enzymatic free radical
oxidation to isoprostanes by [24, 25].
8-isoprostane, which is the most sensitive indicator of
oxidative stress and a perfect marker of redox dysfunc-
tion, has been discovered to play an important role in
some neurological disorders [26–28]. Cysteinyl leukotri-
enes (CysLTs) as biologically active lipid mediators play
a key role in mediating inflammation and involved in
pathological states with an inflammatory components.
They enhance the activity of inflammatory cells such as
monocytes, eosinophils, mast cells and T lymphocytes
[29]. Increased levels of 8-isoprostane, CysLTs, and im-
paired levels of phospholipids and fatty acids have been
recorded in children with autism compared to controls
[30–33].
Social impairments and cognitive deficits are core
features of autism. In autistic patients, difficulties in
understanding the facial expressions of others, atten-
tion deficits, and communication problems are very
common symptoms [34–40]. Moreover, children with
autism have abnormal auditory, visual, tactile and oral
sensory processing that is significantly different from
healthy controls [41–43].
Few studies have drawn correlations between changes
in oxidative stress biomarkers and autism severity.
CARS, SRS and SSP are autism severity scales that have
been designed to measure cognitive deficits, social im-
pairments and sensory dysfunction, respectively. This
study aims to determine the biochemical correlation be-
tween 8-isoprostane, CysLTs, age, and autism severity
scales in an attempt to clarify the role of oxidative stress
(which is indicated by 8-isoprostane levels) and inflam-





The hexane, ethyl acetate, hydrochloric acid and methanol
that were used for extraction of cysteinyl leukotrienes for
analytical experiments were obtained from, Winlab, Merck,
Kock-light laboratory England and BDH, respectively.
Participants
Forty-four children with autism were recruited from the
Autism Research and Treatment Center-King Khalid
University Hospital, and 40 healthy controls were re-
cruited from the Pediatric Laboratory Center of King
Saud Medical City in Riyadh. Parental consent for these
studies was obtained as approved by the ethical guide-
lines of medicine of King Saud University according to
the most recent Declaration of Helsinki (Edinburgh,
2000). A diagnosis of autism was confirmed in all sub-
jects using the Autism Diagnostic Interview-Revised
(ADI-R), the Autism Diagnostic Observation Schedule
(ADOS) and the Developmental, Dimensional and Diag-
nostic Interview (3DI). The mean age of all autistic chil-
dren participating in the study was 7 ± 4 years old, and
all were simple cases. All participants were negative for
fragile x gene mutations. The control group was re-
cruited from the pediatric clinic of King Saud Medical
City in Riyadh and had a mean age of 7 ± 3 years old.
Subjects were excluded from the investigation if they
had (e.g., seizures), psychiatric (e.g., bipolar disorder) or
medical conditions. All participants were screened via
parental interview for current and past physical illness.
Children with known endocrine, cardiovascular, pulmon-
ary, liver, kidney or other medical conditions were ex-
cluded from the study.
Methods
Behavioral assessment
The CARS score was fulfilled as a scale for autism sever-
ity. CARS assesses the child on a scale from one to four
in each of 15 dimensions or symptoms (including the
ability to relate to people; emotional response; imitation;
body use; object use; listening response; fear or nervous-
ness; verbal communication; non-verbal communication;
activity level; level and reliability of intellectual response;
adaptation to change; visual response; taste, smell and
touch response; and general impressions). A total score
of at least 30 strongly suggests the presence of autism.
Children who score between 30 and 36 have mild to
moderate autism while those with scores between 37
and 60 points have severe autism [44]. SRS is the first
widely used quantitative parent/teacher-report measure
of autistic behaviors and is completed in 15 to 20 min. A
total SRS score of 76 or higher is considered severe and
is strongly associated with a clinical diagnosis of autistic
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disorder. A score between 60 and 75 is in the mild to
moderate range of social impairment [45].
The Short Sensory Profile [46] is a 38-item question-
naire intended to rate a variety of sensory impairments.
Each item on the SSP is measured on a 5-point Likert
scale. Domain scores are measured in the areas of tactile
sensitivity, taste/smell sensitivity, movement sensitivity,
seeking sensation, auditory filtering, low energy levels,
and visual/auditory sensitivity. Domain scores and the
overall sensory response are categorized as typical per-
formance, probable difference from typical performance,
or definite difference from typical performance. Scores
less than 142 indicate severe performance (definite dif-
ference from typical performance), scores between 142
and 152 indicate mild to moderate performance (probable
difference from typical performance) and scores between
153 and 190 indicate typical performance. The SSP can
provide information about the sensory processing skills
of children with autism to assist occupational thera-
pists in assessing and planning interventions for these
children [41].
Blood sample collection
After overnight fasting, blood samples from 44 autistic
children and 40 healthy controls were drawn from the
arm by a qualified lab technician. Blood was taken into
3-ml blood collection tubes containing EDTA, and sam-
ples were immediately centrifuged at 4 °C at 3000 g for
20 min. The plasma was decanted, dispensed into four
0.75 ml aliquots (to avoid multiple freeze-thaws cycles)
and stored at −80 °C until analysis.
Biochemical assays
The concentrations of 8-isoprostane and CysLTs were
measured in plasma of control and autistic subjects. All
biochemical analyses were performed in duplicate, and
the mean values were reported.
Sample extraction for cysteinyl leukotrienes
300 μl of plasma samples were acidified with 30 μl of
1 M HCl and allowed to incubate at 4 °C. Samples were
then centrifuged for 2 min at 2000 rpm and the superna-
tants were transferred to a fresh tube. Solid phase ex-
traction C-18 cartridges were prepared by washing with
150 μl of methanol followed by 250 μl of double distilled
water. Samples were applied on the column and allowed
to flow through by centrifugation at 2000 rpm. The col-
umn for each sample was rinsed with 250 μl of double
distilled water followed by 250 μl of hexane. After the
hexane rinse, each column was allowed to dry for
10 min. CysLTs were eluted with 150 μl of methanol.
Table 1 Levels of 8-isoprostane and CysLTs in autistic patients compared to control participants
Parameters Group N Mean ± S.D. P value
8-Isoprostane (pg/ml) Control 40 24.03 ± 2.65 0.001*
Autistic Patients 44 103.27 ± 12.56
Autism (severe in CARS) 21 102.09 ± 11.11 0.556**
Autism (mild to moderate in CARS) 23 104.35 ± 13.91
Autism (severe in SRS) 5 103.35 ± 12.47 0.741**
Autism (mild to moderate in SRS) 16 101.19 ± 12.60
Autism (mild to moderate in sensory) 24 97.66 ± 12.65 0.001**
Autism (severe in sensory) 17 111.17 ± 8.67
Age (less than 7) 23 107.08 ± 12.19 0.034**
Age (more than 7) 21 99.10 ± 11.86
Cysteinyl leukotrienes (ng/ml) Control 20 0.394 ± 0.108 0.001*
Autistic Patients 29 0.658 ± 0.199
Autism (mild to moderate in CARS) 11 0.642 ± 0.197 0.738**
Autism (severe in CARS) 18 0.668 ± 0.205
Autism (mild to moderate in SRS) 1 0.602 ± 0.000 0.382**
Autism (severe in SRS) 9 0.759 ± 0.161
Autism (mild to moderate in sensory) 19 0.573 ± 0.156 0.001**
Autism (severe in sensory) 10 0.821 ± 0.170
Age (less than 7) 15 0.708 ± 0.210 0.164**
Age (more than 7) 14 0.605 ± 0.177
*P value between control and autistic groups
**P value between mild to moderate and severe in CARS, SRS, SSP and age
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Finally, the samples were dried and 200 μl of assay buf-
fer were added.
Assay of cysteinyl leukotriene
Cysteinyl leukotrienes were measured using an ELISA
kit, a product of Invitrogen, USA. This ELISA kit is a
competitive immunoassay for the quantitative determin-
ation of CysLTs in plasma. The kit measures three of the
major metabolites of LTA4, LTC4, LTD4 and LTE4.
Assay of 8-isoprostane (8-iso-PGF2α)
The levels of 8-isoprostane were measured using a non-
radioactive, safe ELISA kit, a product of MyBioSource.
This assay employs the quantitative sandwich enzyme
immunoassay technique. The minimum detectable con-
centration of human 8-isoprostane was typically less
than 19.5 pg/ml.
Statistical analysis
SPSS computer software was used for statistical analyses.
Results were expressed as the mean ± SD and all statis-
tical comparisons were made by independent t-tests with
p ≤ 0.05 considered as significant. Receiver Operating
Characteristic (ROC) analysis was performed as a com-
prehensive way to measure the accuracy of the assessed
biomarkers. The area under the curve (AUC) provided a
useful metric to compare different biomarkers. An AUC
value close to 1 indicated an excellent diagnostic and
predictive marker; however, a curve that was close to the
diagonal (AUC = 0.5) had no diagnostic utility. An AUC
close to 1 is always accompanied by satisfactory values
of specificity and sensitivity of the biomarker. Moreover,
the predictiveness diagrams of the measured parameters
were drawn, in which the x-axis represents percentile
rank of the biomarker, the y-axis represents the prob-
ability of identifying the disease, and the horizontal line
is the prevalence of the disease as determined by the
Biostat 16 computer program.
Results
Levels of 8-isoprostane and CysLTs were compared be-
tween autism patients with different degrees of autism
severity (mild to moderate or severe) and normally de-
veloped controls. Autism patients were classified accord-
ing to their recorded CARS, SRS and SSP scores with
age (i.e., less and more than 7 years) (Table 1). Data are
presented as the mean ± SD of a maximum number of
44 autism patients compared to 40 controls. The signifi-
cant differences between both groups and subgroups of
patients with autism were presented in Table 1 and Fig. 1.
It was observed that the measured parameters differed
significantly between autism patients and controls, while
there were no significant differences between subgroups



















Control Less than 7 More than 7
Cysteinylleukotriens
a b
Fig. 1 a 8-isoprostaneand (b) CysLTs levels in autistic and control age groups. The mean value for each group is designated by a line
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impairments (mild to moderate and severe). Autistic pa-
tients with sensory dysfunction showed strong signifi-
cance levels between mild to moderate and severe
subgroups for both parameters. The levels of 8-
isoprostane were significantly correlated with age while
CysLTs levels did not show any significant differences.
Figure 2 demonstrates a normal distribution for the two
studied parameters. Moreover, the figure represents the
highest and lowest level of 8-isoprostane andCysLTs
both for autistic patients and controls. From the normal
distribution (Fig. 2a & b) of 8-isoprostane, it can be eas-
ily observed that while the highest recorded value in the
control group was 30 pg/ml, the lowest value in the aut-
istic group was 80 pg/ml. For CysLTs, 18 out of 30 con-
trol participants exhibited concentration levels less than
0.6 ng/ml; however, 17 out of 29 autistic patients dem-
onstrated CysLTs values higher than 0.6 ng/ml.
Sensitivity and specificity are the basic measures of the
accuracy of a diagnostic test. These parameters describe
the ability of a test to correctly diagnose disease when dis-
ease is actually present and to correctly rule out disease
when disease is truly absent. ROC show that AUC for 8-
isoprostane was one, while that for CysLTs was slightly
less than one. By using a statistical analysis program
Fig. 2 Normal distribution for control and autistic groups for (a) 8-isoprostane (pg/ml) and (b) CysLTs (ng/ml)
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(SPSS) which includes the Pearson correlation test, a cor-
relation was made between all parameters; the results
showed that there was a correlation significance difference
between the parameters shown in Table 2. For autistic
individuals, the relationship between the levels of 8-
isoprostane, CysLTs and severity of autism that was
measured by the CARS, SRS, and SSP scores were also
evaluated. There was a positive correlation between 8-
isoprostane and CysLTs (R = 0.686, p < 0.001) and there
were negative correlations between 8-isoprostane,
CysLTs, and SSP scores (R = −0.517, p < 0.05 and R =
−0.615, p < 0.001). Additionally, age had a significant
negative correlation with 8-isoprostane plasma levels
(R = −0.376, p < 0.012) and had a significant positive
correlation with SSP scores (R = 0.296, p < 0.043).
Discussion
It is well known that oxidative stress plays a critical role in
many neurodevelopmental disorders [47, 48]. 8-isoprostane
is the most characterized compound that provided a reli-
able index of unique bioactive products of lipid peroxida-
tion and oxidative stress in a variety of clinical settings.
In the present study, significant increase in the level of
8-isoprostane was recorded in autistic patients compared
to controls. This can demonstrate the role of
inflammation as etiological mechanism in autism as it is
consistent with previous studies that show high 8-
isoprostane level in plasma, urine or breath from patients
suffering from inflammation [49–52]. The normal range
of 8-isoprostane in the blood of humans is between 20
and 80 pg/ml, and based on the data obtained herein, 8-
isoprostane levels in autistic children are much higher
than the upper limit of the normal range [53]. In the
present study, although a four-fold increase in 8-
isoprostane was detected in autistic children compared to
controls, a relationship between 8-isoprostane and social
or cognitive impairments was completely absent. How-
ever, a significant correlation between 8-isoprostane and
sensory dysfunction was clearly observed. The significant
difference in the 8-isoprostane level between the two stud-
ied age groups (<7 or >7) can help to suggest that oxida-
tive stress is an early event that may play an important
role in the pathogenesis of autism. The observed increase
in 8-isoprostane are in good agreement with many previ-
ous studies that collectively demonstrate the usefulness of
this marker for diagnosing autism [15, 54, 55]. In a previ-
ous study conducted by Ming et al., a significant increase
of l urinary excretion of 8-isoprostane was recorded in
children with autism compared to age-matched controls
[15]. Plasma levels of 8-isoprostane have also been corre-
lated with anti-neural antibodies as a measure of auto-
immunity as a pathological mechanism in autism [54, 56].
Moreover, the significantly high level of 8-isoprostane
reported in the present study may be related to the brain
hypoperfusion that has been reported in autistic children
compared to controls. Yuemang et al. observed a correl-
ation between 8-isoprostane and abnormal blood flow in
autism because of the role of 8-isoprostane in platelet
aggregation and vaso-constriction [57]. Moreover, mul-
tiple neuroimaging studies have noted the relationship
between oxidative stress and vascular homeostasis in the
pathogenesis of autism, including the possible influence
of 8-isoprostane on tissue perfusion [58, 59].
Table 2 Pearson’s correlations between the different studied
variables
Parameters R (Pearson Correlation) Sig.
SSP ~ Age 0.296b 0.043
SSP ~ 8-isoprostane (pg/ml) −0.517a 0.001
SSP ~ CysLTs (ng/ml) −0.615a 0.001
Age ~ 8-isoprostane (pg/ml) −0.376b 0.012
8-isoprostane (pg/ml) ~ CysLTs(ng/ml) 0.686a 0.001
a Correlation is significant at the 0.001 level
b Correlation is significant at the 0.05 level
Table 3 Values of area under the ROC curve (AUC), sensitivity and specificity for the optimal cut-off point for mild to moderate
CARS, SRS, SSP and age
Parameters Scales AUC Cutoff value Sensitivity % Specificity%
8-Isoprostane (pg/ml) CARS 1.000 56.165 100.0 100.0
SRS 1.000 58.465 100.0 100.0
SSP 1.000 55.049 100.0 100.0
Age (Less than 7 years) 1.000 56.981 100.0 100.0
Age (More than 7 years) 1.000 55.049 100.0 100.0
CysLTs (ng/ml) CARS 0.900 0.463 90.9 90.0
SRS 0.925 0.530 100.0 90.0
SSP 0.854 0.453 89.5 85.0
Age (Less than 7 years) 0.943 0.416 100.0 80.0
Age (More than 7 years) 0.845 0.479 85.7 90.0
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Glutamate is the main excitatory neurotransmitter in
the CNS; it plays an important role in the brain and can
cause damage in response to neurological dysfunction. A
strong correlation between 8-isoprostane and glutamate
excitotoxicity as a phenotype repeatedly recorded in aut-
ism has been reported in several studies [47, 60–62].
There is increasing evidence that CysLTs may play a role
in CNS activity. In the present study, although the levels of
CysLTs were significantly higher in autistic children com-
pared to healthy controls, there was no association with
age, CARS, or SRS. Contrarily, CysLTs levels were signifi-
cantly associated with the severity of sensory dysfunction.
The deleterious effects of CysLTs usually occur through
the induction of superoxide radicals as a marker of oxida-
tive stress [63]. While CysLTs do not directly stimulate
sensory nerves, they induce the release of increased
amounts of neuropeptides from tachykinergic nerves
under the influence of action potentials [64, 65]. This sug-
gests that CysLTs may potentiate neural phenomena such
as neurogenic inflammation, and excitotoxicity [66, 67]. In
Fig. 3 ROC curves for 8-isoprostane and CysLTs
Fig. 4 The predictiveness curves as an assessment of the performance of 8-isoprostane and CysLTs in autism risk prediction in the Saudi population.
The two measured parameters showed adequate predictive power
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different neurological diseases, CysLT1 receptor mRNA
has been found to be up-regulated in neurons, macro-
phages and proliferated astrocytes, suggesting a possible
regulatory role in the mediation of different phases of
neuro-inflammation [68, 69]. These compounds have been
associated with brain edema formation and disruption of
the BBB [70]. The obtained alteration in 8-isoprostane
and CysLTs reported in the present study, can find sup-
port in the record of Das [71] showing that changes in the
metabolism of AA and other PUFAs result in excess pro-
duction of proinflammatory cytokines and inflammatory
lipid mediators and less production of anti-inflammatory
cytokines and bioactive lipids that ultimately induce the
development of autism.
The significant positive correlations discovered herein
between 8-isoprostane and CysLTs (Table 2) confirmed
an association between impaired phospholipid metabol-
ism, inflammation, nutritional status and oxidative stress
in the etiopathology of autism [68–72]. The discovered
negative correlation between 8-isoprostane as a marker
of oxidative stress and age may explain the remarkable
improvement of autistic patients near adulthood. This
suggestion has been supported in two previous studies
that showed an improvement of phenotypes in a major-
ity of autistic patients during the transition to adulthood
[73, 74]. Fletcher-Watson et al. [75] concluded that
adults with autism were faster and more accurate at de-
tecting eye gaze than controls. Moreover, restricted re-
petitive behavior was less frequent and less severe
among older individuals than younger individuals, sug-
gesting that autism may somewhat diminishes with age.
Although there was no correlation between CARS,
SRS or either of the oxidative stress markers in the
present study, previous studies have shown that oxi-
dative stress causes cognitive decline and memory
loss [76]. The effectiveness of using both of the mea-
sured parameters for the correct diagnosis of autism
can be easily supported through ROC analysis (Table 3
and Fig. 3 a and b). Both biomarkers exhibited high
AUC values together with satisfactory specificity and
sensitivity. In fact, a key issue in performing an inter-
vention trial with antioxidants is establishing whether
the treatment decreases oxidative stress in study sub-
jects and at what dose. Measurement of the level of
lipid peroxidation, which is reflected by 8-isoprostane
concentrations in biological fluids, may help to iden-
tify patients who are most likely to benefit from anti-
oxidant treatments [77, 78]. This can be supported by
the illustrated predictiveness curves (Fig. 4 a and b).
While both of the measured oxidative stress bio-
markers demonstrate perfect predictiveness curves
herein, 8-isoprostane shows more predictive value
than CysLT1 and thus can be used to follow-up fu-
ture suggested antioxidant intervention strategies.
Conclusions
In summary, the data presented herein indicate that
8-isoprostane and CysLTs are reliable biomarker for
oxidative stress that present in autism, and can be
easily measured from a blood sample. 8-isoprostane
and CysLTs, known as lipid mediators that are ex-
creted by activated glial cells under stimulation of
ROS. Many studies of autism revealed that those lipid
mediators arising from neuro-inflammation is consist-
ent with all biochemical, pathophysiological data that
done on autism patients and can easily related to the
nutritional factors [72, 79].
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